Lubrizol announces US$15 million investment to expand medical solution capability

Lubrizol Corporation announced an investment of more than US$15 million in its LifeSciences business to serve the growing market for medical device development and contract manufacturing.

This capital investment will expand multiple facilities and increase Lubrizol LifeSciences' in-house engineering capacity for both silicone and thermoplastic products.

Part of the investment will go to improving Vesta's thermoplastic capabilities to include: tip forming, tube flaring, pad printing, hole punching/drilling, precision cutting, reflow and braided tubing lamination, etc.

Acquired by Lubrizol in August 2014, Vesta offers custom contract manufacturing services, including precision silicone and thermoplastic extrusion as well as comprehensive silicone fabrication.

"When customers partner with Lubrizol LifeSciences, they benefit from working with us at every stage in their development process," stated Robert Miller, Global Business Director, Medical Devices, Lubrizol. "With a long history of polymer expertise and significant investment, Lubrizol LifeSciences is positioned to offer full-service development for next generation medical and pharmaceutical innovations."

Lubrizol made the announcement at MD&M West 2016, which took place from February 9-11 in Anaheim, the US.